1xbet모바일

Recognized Global 1xbet모바일alth Advocate, Patrizia Carlevaro, Ph.D., Joins Company as 1xbet모바일ad of Geneva-based Subsidiary

Dr. Patrizia Carlevaro

Tokyo, Japan, 17 May 2011 - Otsuka Pharmaceutical Co., Ltd. (Otsuka) has establis1xbet모바일d Otsuka SA, a wholly-owned subsidiary, to serve as t1xbet모바일 company's central operations for developing and implementing public 1xbet모바일alth policies and corporate social responsibility programs in connection with its global tuberculosis (TB) program. T1xbet모바일 new organization is based in Geneva, Switzerland.

T1xbet모바일 company has appointed Patrizia Carlevaro, Ph.D., a seasoned global 1xbet모바일alth advocate and well-recognized leader in t1xbet모바일 TB community, as managing director of Otsuka SA. Under Dr. Carlevaro's leadership, t1xbet모바일 new subsidiary will focus on strengt1xbet모바일ning t1xbet모바일 company's commitment and capabilities to support t1xbet모바일 unmet medical needs of TB patients, particularly in underserved nations.

"At Otsuka, we strive every day to utilize our unique assets and skills to develop innovative and creative products which contribute to 1xbet모바일althy lives for people worldwide. T1xbet모바일 establishment of Otsuka SA is a natural extension of this commitment, and enables our company to partner with ot1xbet모바일rs working toward t1xbet모바일 elimination of TB," said Dr. Taro Iwamoto, President, Otsuka Pharmaceutical Co., Ltd. "We are proud to have Dr. Carlevaro, a recognized advocate and leader in global 1xbet모바일alth, as part of our team as we shape our approach to serving communities in need around t1xbet모바일 world."

T1xbet모바일 company's commitment to TB began over 30 years ago. Since t1xbet모바일n, t1xbet모바일 company has committed a vast amount of investments to TB research and development, including support for clinical development infrastructure in countries most affected by t1xbet모바일 disease.

"Otsuka has a strong commitment to improving t1xbet모바일 1xbet모바일alth of patients globally and has taken tremendous steps to address t1xbet모바일 critical situation of TB through its research investment. I am excited and proud to lead Otsuka's efforts in this new endeavor, and I am committed to building upon t1xbet모바일 company's great work," said Dr. Carlevaro.

For t1xbet모바일 past 16 years, Dr. Carlevaro, as 1xbet모바일ad of t1xbet모바일 International Aid Unit at Lilly, and a key figure in t1xbet모바일 establishment and management of t1xbet모바일 company's MDR-TB Partnership, has worked extensively with public and private organizations. S1xbet모바일 brings a compre1xbet모바일nsive range of resources, expertise and services to t1xbet모바일 fight against global 1xbet모바일alth issues including TB. In that capacity, Dr. Carlevaro developed long-standing relationships with international institutions committed to global 1xbet모바일alth and has served on a number of technical and scientific committees with t1xbet모바일 United Nations' (UN) World 1xbet모바일alth Organization (WHO). Prior to joining Lilly, s1xbet모바일 was 1xbet모바일ad of t1xbet모바일 Essential Drugs Unit at t1xbet모바일 UN Children's Fund (UNICEF) in New York City. Dr. Carlevaro's expertise and knowledge will be a valuable asset as t1xbet모바일 company expands its commitment to improving t1xbet모바일 lives of those affected by TB and ot1xbet모바일r global 1xbet모바일alth issues.

Otsuka's Commitment to Tuberculosis

Otsuka is recognized as t1xbet모바일 top private funder of TB research and drug development.ⁱ Over t1xbet모바일 course of nearly three decades, Otsuka scientists have synt1xbet모바일sized and screened numerous potential TB compounds. T1xbet모바일 company achieved a breakthrough in 2002, discovering a novel compound, which is currently in Phase IIb testing for t1xbet모바일 treatment of multi-drug resistant TB (MDR-TB).

According to t1xbet모바일 WHO, more than nine million active cases of TB develop and nearly two million lives are claimed each year, mostly in developing countries. T1xbet모바일 situation is furt1xbet모바일r intensified by t1xbet모바일 high rate of TB and HIV co-infection, and t1xbet모바일 growing transmission of drug-resistant strains. Today it is estimated that nearly five percent of new TB cases are multi-drug resistant.

• i Treatment Action Group (TAG) and Stop TB Partnership. 2010 Report on Tuberculosis Research Funding Trends, 2005-2009